Pharmaceuticals

Roche's CT-388 posts impressive Phase II results, positioning it as a powerful new rival to Zepbound and Wegovy in the booming obesity drug market.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

A strategic investment from Krieger Capital will fuel Global Key Solutions' AI platform, which transforms complex regulatory data into actionable safety insights.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

The acquisition strengthens the independent distributor's hold on the booming plasma therapy market, promising wider access to critical, complex medications.

Avant Technologies is evaluating a therapy to protect insulin cells from immune attack, a breakthrough that could end the need for harsh drugs.

A new COVID-19 drug targets patients who can't take Paxlovid, while a once-a-month pill could revolutionize how we prevent seasonal influenza.

With new VP of Sales David Florez, Peer AI aims to accelerate its mission of transforming regulatory documentation as the pharma industry moves beyond AI pilots.

Leios Therapeutics partners with BNC Korea, securing a key investment and pathway to Asia's lucrative body contouring market for its 10XB-101 injectable.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

On its 50th anniversary, CDMO specialist Coating Place leverages a major investment by appointing two industry veterans to drive its next chapter of expansion.

Insilico Medicine's AI-powered drug ISM8969, a brain-penetrant inhibitor, has been cleared by the FDA for clinical trials in Parkinson's disease.

With strong Q1 momentum, Standex faces a complex market. Its upcoming Q2 results will offer key insights into global manufacturing and corporate strategy.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

Acrivon Therapeutics to unveil pivotal data showing high response rates for its targeted drug ACR-368 in an aggressive endometrial cancer subtype.

Ontario's new FAST program provides accelerated funding for two key cancer drugs, cutting patient wait times and setting a new standard for access in Canada.

A single patient with a debilitating eye pain condition gains access to an investigational therapy, offering hope where no approved treatments exist.

New 24-month data suggests a novel drug could improve kidney function and reduce side effects for transplant patients, challenging a decades-old standard.

Swiss biotech GeNeuro suspends trading, awaiting a critical court ruling on its debt moratorium that will decide its fate and the future of its novel drugs.

Frost & Sullivan recognizes Verana Health as the top innovator in real-world evidence, a move solidifying its market dominance after a key oncology merger.